A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT05071664
- Phase
- PHASE2
- Status
- Completed
Conditions
- Arthritis, Psoriatic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Guselkumab — DRUGGuselkumab will be administered as a SC injection.
- Golimumab — DRUGGolimumab will be administered as a SC injection.
- Placebo — DRUGPlacebo will be administered as a SC injection.
Study Details
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
Key Dates
- Start date
- Oct 25, 2021
- Status verified
- Apr 2026
- Primary completion
- May 14, 2024
- Completion
- Aug 6, 2024
Study Design
- Enrollment
- 91 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1: Guselkumab and GolimumabParticipants will receive subcutaneous (SC) guselkumab and golimumab.
- Active Comparator: Group 2: Guselkumab and PlaceboParticipants will receive SC guselkumab and placebo.
Primary Outcome Measure
Percentage of Participants who Achieve Minimal Disease Activity (MDA) at Week 24 [ Time Frame: Week 24 ]
Locations (20)
Find similar trials in Phoenix, AZ
By research site
Related Studies
- IMPACT - AndHealth Autoimmune Research RegistryRecruiting · AndHealth · Columbus, Ohio
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePHASE3 · Recruiting · MoonLake Immunotherapeutics AG · Avondale, Arizona
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPHASE3 · Recruiting · Janssen Research & Development, LLC · Atlanta, Georgia
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPHASE3 · Recruiting · Janssen Research & Development, LLC · Glendale, Arizona